Compare i-80 Gold Corp. Common Shares (IAUX) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
i-80 Gold Corp. Common Shares vs Eli Lilly And Co — how do they compare? i-80 Gold Corp. Common Shares trades at $1.48 (market cap $1.26B), while Eli Lilly And Co trades at $1,227.4 (market cap $1.08T). The key difference: Eli Lilly And Co is far larger — about 857.1× i-80 Gold Corp. Common Shares's market cap, and Eli Lilly And Co pays a 0.57% dividend while i-80 Gold Corp. Common Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold i-80 Gold Corp. Common Shares for 0 Days and Eli Lilly And Co for 94 Days on average.
| IAUX | LLY | |
|---|---|---|
Market Cap | $1.26B | $1.08T |
Volume | 10,665,602 | 2,520,401 |
Sector | Basic Materials | Health |
52-Week High | $2.08 | $1.28K |
52-Week Low | $0.89 | $799.57 |
Typical Hold Time | 0 Days | 94 Days |
Enterprise Value | $1.24B | $1.12T |
Dividend Yield | — | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IAUX trades at $1.54, down 2.53% today, with a neutral technical signal. The company shows significant financial challenges with a -198.82% net income margin and negative ROE of -71.66%, though revenue grew from $95M in 2025 to $130M in 2026. Recent positive developments include CEO purchasing 1 million shares and feasibility studies showing strong potential for Nevada gold projects. Analyst consensus remains unanimously bullish with 3 buy ratings.
While facing substantial profitability challenges, IAUX's development pipeline and CEO confidence suggest long-term potential. Key risks include persistent negative cash flow from operations and high debt levels. The stock presents a high-risk, high-reward opportunity dependent on successful project execution and gold price stability.
Eli Lilly (LLY) trades at $1,166.51, down 1.36% on the day, amid strong fundamentals with revenue surging to $65.18B in 2025 and net income reaching $20.64B. The stock exhibits a bullish technical trend, supported by moving averages, with key resistance near $1,190. Recent news highlights promising pipeline developments in weight-loss drugs, reinforcing growth prospects.
Outlook remains positive given robust earnings beats, high analyst buy ratings (73%), and a consensus price target of $1,350. Risks include competitive pressures and execution challenges in scaling production. The stock's premium valuation (P/E 39.16) warrants monitoring, but strong cash flow and innovation pipeline support long-term upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About i-80 Gold Corp. Common Shares
i-80 Gold Corp. is a mining company focused on developing and operating gold and precious-metals projects in Nevada, using a hub-and-spoke model centered on a processing facility to support multiple mine sites in the state.
Read more on IAUX →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
